Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy-Reference-Cited by-同舟云学术

Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy

Published:2017-03-27 Issue:5 Volume:96 Page:547-555
ISSN:0001-6349
Container-title:Acta Obstetricia et Gynecologica Scandinavica
language:en
Short-container-title:Acta Obstet Gynecol Scand

Author:

Johansen Nora¹²³^ORCID,Liavaag Astrid H.¹²,Iversen Ole-Erik⁴⁵,Dørum Anne⁶,Braaten Tonje⁷,Michelsen Trond M.²⁸⁹

Affiliation:

1. Department of Gynecology; Sørlandet Hospital Arendal; Arendal Norway

2. Research Unit; Sørlandet Hospital; Arendal Norway

3. Faculty of Medicine; University of Oslo; Oslo Norway

4. Department of Clinical Science; University of Bergen; Bergen Norway

5. Department of Gynecology and Obstetrics; Haukeland University Hospital; Bergen Norway

6. Department of Gynecological Oncology; Oslo University Hospital Radiumhospitalet; University of Oslo; Oslo Norway

7. Institute of Community Medicine; University of Tromsø; Tromsø Norway

8. Division of Gynecology and Obstetrics; Department of Obstetrics; Oslo University Hospital Rikshospitalet; Oslo Norway

9. Norwegian National Advisory Unit on Women's Health; Oslo University Hospital; Oslo Norway

Funder

Sørlandet Hospital HF

Norske Kvinners Sanitetsforening

Publisher

Wiley

Subject

Obstetrics and Gynecology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/aogs.13120/fullpdf

Reference37 articles.

1. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases;Pal;Cancer,2005

2. Meta-analysis of BRCA1 and BRCA2 penetrance;Chen;J Clin Oncol,2007

3. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation;Finch;JAMA,2006

4. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers;Rebbeck;J Natl Cancer Inst,2009

5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian 2016 https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine;Gynecologic Oncology;2024-11

2. Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy;Obstetrics & Gynecology Science;2024-07-15

3. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with BRCA1/2 Pathogenic Variants: A Population-Based Retrospective Cohort Study;Current Oncology;2023-10-22

4. Counselling of path_BRCA carriers who are considering risk-reducing oophorectomy;Post Reproductive Health;2023-02-09

5. Heart Failure in Menopause: Treatment and New Approaches;International Journal of Molecular Sciences;2022-12-01